Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
Phase 1/2 Withdrawn
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Phase 1/2 Withdrawn
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Phase 1/2 Withdrawn
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Phase 1/2 Withdrawn
Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms
Phase 1/2 Withdrawn
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase 1/2 Withdrawn
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Phase 1/2 Withdrawn
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Phase 1/2 Withdrawn
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
Phase 1/2 Withdrawn
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 1/2 Withdrawn
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Phase 1/2 Withdrawn
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Phase 1/2 Withdrawn
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
Phase 1/2 Withdrawn
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
Phase 1/2 Withdrawn
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
Phase 1/2 Withdrawn
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
Phase 1/2 Withdrawn
AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS
Phase 1/2 Withdrawn
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Phase 1/2 Withdrawn
Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
Phase 1/2 Withdrawn